Q1 2026 Peptide Industry Roundup: Innovations in Metabolic Health, Oral Delivery, and Radioligands

The start of 2026 has shown that the "Peptide Renaissance" is only accelerating. From the landmark approval of the first oral peptide for psoriasis to the massive expansion of the GLP-1 landscape, synthetic peptides continue to move from niche biologics to front-line primary care.

Here is a look at the key developments from across the industry so far in 2026.

Metabolic Health & Obesity

The metabolic sector remains at the center of synthetic peptide production. The focus has shifted from simple GLP-1 analogs to triple agonists and long-acting amylin analogs.

Eli Lilly reported that Retatrutide, a triple-agonist peptide (GLP-1/GIP/Glucagon), significantly reduced A1C and body weight in Phase 3 trials. This 3-in-1 approach highlights the increasing complexity required in large-scale peptide assembly.

Roche and its subsidiary Genentech announced positive Phase II trial results for petrelintide, a long-acting peptide therapy modeled after the hormone amylin. The companies aim to provide a potent weight-loss alternative that offers better gastrointestinal tolerability than traditional GLP-1 receptor agonists.

Concurrently, Antag Therapeutics is advancing their own amylin and GIP-receptor antagonist program in preclinical studies.

Kailera Therapeutics reported positive results for their Phase 2 trial of Ribupatide, their oral GLP-1/GIP dual agonist

Dermatology & Immunology: A Win for Oral Peptides

More developers are achieving the milestone of transitioning injectable peptide biologics into stable oral tablet forms.

The FDA approved Icotrokinra (J&J / Protagonist), marking a historic milestone: the first targeted oral peptide therapy for moderate-to-severe plaque psoriasis.

Soligenix received Orphan Drug Designation for SGX945, a synthetic peptide candidate targeting Behçet’s Disease, further expanding the footprint of peptides in rare immunological conditions.

Oncology & Radioligands

Peptides are increasingly used as homing devices to deliver radioactive isotopes or chemo directly to tumors.

Novartis continued its dominance in the radioligand therapy space by licensing a peptide-based asset from Zonsen Peplib. This deal emphasizes the growing demand for high-purity peptides that can be reliably conjugated to radioactive isotopes.

The FDA cleared the IND for Avacta’s AVA6103. This peptide-drug conjugate utilizes a specialized peptide linker designed to release chemotherapy only when it encounters the specific microenvironment of a tumor.

Parabilis Medicines announced preliminary clinical data showing that its first-in-class therapy, zolucatetide, significantly reduced the number and size of duodenal polyps in a patient with familial adenomatous polyposis (FAP).

Rare Diseases & Bone Health

Synthetic peptide analogs are proving vital in hormone replacement and structural repair.

BioMarin released long-term data for Voxzogo (Vosoritide), showing sustained growth benefits for children with achondroplasia.

Cerapedics received expanded approval for its P-15 peptide-enhanced bone graft, which utilizes a specific 15-amino acid sequence to mimic natural bone-building proteins.

Entera Bio & Opko Health are moving forward with an oral, long-acting Parathyroid Hormone (PTH) peptide for hypoparathyroidism.

Macrocyclics and Synthesis Expansion

To support this clinical explosion, peptide manufacturing technology must evolve.

Unnatural Products and Novartis have entered into a strategic collaboration to discover and develop next-generation macrocyclic peptide therapeutics for cardiovascular targets. By combining Unnatural Products' AI-driven discovery platform with Novartis' expertise in drug development, the partnership aims to create highly permeable, orally bioavailable peptides that can address previously "undruggable" disease pathways.

CordenPharma announced the expansion of its peptide development lab in Boulder, Colorado, specifically to expand its peptide development and analytical services. Located adjacent to the company’s existing manufacturing site, the laboratory will streamline the production of advanced peptide active pharmaceutical ingredients (APIs) from early-stage development through commercialization.